Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

SIMBA in Irritable Bowel Syndrome (IBS)

NCT: NCT07882953 · NOT_YET_RECRUITING

NCT IDNCT07882953

StatusNOT_YET_RECRUITING

SponsorUniversity of Calgary (OTHER)

First posted2026-10-20

Last updated2026-10-20

Brief Summary

This study is intended to characterize longitudinal changes in the small intestinal microbiome following rifaximin treatment in participants with Irritable Bowel Syndrome (IBS) over a 12 week period.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑